The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...
The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...
GlobalData on MSN
GSK’s Blenrep gains FDA approval for myeloma treatment
The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.
MedPage Today on MSN
CAR-T Drug for Myeloma Hit With New Boxed Warning
Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...
In the late-stage MajesTEC-3 trial, Tecvayli plus the subcutaneous formulation of J&J’s antibody drug Darzalex beat ...
MedPage Today on MSN
Cancer Drug Pulled From Market Regains FDA Approval
It's been a roller coaster ride for the drug ever since it was granted accelerated approval in 2020 for the treatment of ...
TipRanks on MSN
Bristol-Myers Squibb’s New Study on Multiple Myeloma Maintenance Therapy: A Potential Market Game-Changer
Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Bristol-Myers Squibb Company is ...
Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...
The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...
Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback